Stock MCRB SERES THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-18 EDT 		5-day change 1st Jan Change
0.7104 USD +5.89% Intraday chart for Seres Therapeutics, Inc. -4.72% -49.26%
06-11 Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic CI
06-07 Canaccord Genuity Adjusts Price Target on Seres Therapeutics to $10 From $15, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
AQ
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
SERES THERAPEUTICS ENTERS INTO MEMORANDUM OF UNDERSTANDING FOR VOWST ASSET SALE TO NESTLE HEALTH SCIENCE
AQ
Seres Therapeutics - Nestle Health Science agrees to acquire global rights to VOWST, product it launched in June 2023
AQ
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
PR
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
AQ
Seres Therapeutics: Q1 Earnings Snapshot
AQ
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
BU
Seres Therapeutics : Accelaration/Increase of Financial Obligation - Form 8-K
PU
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
BU
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
BU
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
BU
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
BU
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
BU
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MCRB Stock
  4. News Seres Therapeutics, Inc.
  5. Press Releases